SlideShare a Scribd company logo
HPLC
Principle, Uses, Interpretation,
Results
MODERATOR: PRESENTED BY:
Dr. Maneesh Sulya Dr. Parul Murab
HPLC?
HIGH PERFORMANCE: Originally referred as high pressure liquid
chromatography since high pressure is applied using a pump
system.
Due to its high efficiency and performance, it is now referred as high
performance.
LIQUID CHROMATOGRAPHY: A physical method of separation,
identification and quantification of components in which
components to be separated are distributed between a liquid
mobile phase and a solid stationary phase in a definite direction.
INTRODUCTION: CHROMATOGRAPHY
 Chromatography is a physical method of separation between:
STATIONARY PHASE MOBILE PHASE
The substance on which adsorption Solvent which carries the analyte.
of analyte takes place.
Can be solid, gel, liquid or Can be liquid or gas.
combination.
 TECHNIQUE IS DIVIDED ON BASIS OF:
Chromatographic bed: column or planar
Physical state of mobile phase: gas or liquid
Separation mechanism: adsorption, ion exchange , ion pair , affinity, gel permeation
Elution techniques: Isocratic , gradient
Scale of operation: analytical(no recovery) , preparative
SYSTEM TYPE?
 LIQUID CHROMATOGRAPHY: Liquid mobile phase
 COLUMN CHROMATOGRAPHY: Adsorption of substance on stationary phase.
-Separation of adsorbed substance using mobile phase.
-recovery of individual components by continuous flow of
mobile phase.
 HIGH PRESSURE CHROMATOGRAPHY-15-75kg/cm²
 ION EXCHANGE( cation) OR ADSORPTION MECHANISM or both.
 GRADIENT ELUTION TECHNIQUE
 REVERSED PHASE Chromatography-non polar stationary phase and polar mobile phase.
SILICA GEL
PRINCIPLE
Mixture of molecules
(normal and variant
haemoglobin) with a net
positive charge is separated
into its components by their
adsorption onto a negatively
charged stationary
phase(resin) in
chromatographic
column/cartridge.
Cations in the mobile phase(buffer A
and B) competes with adsorbed
proteins(haemoglobin molecules) for
anionic binding sites.
Buffer A: weak affinity for anionic
binding sites.
Buffer B: strong affinity for anionic
binding sites.
The adsorbed positively charged
haemoglobin molecules are eluted from
column into liquid phase at a rate
related to their affinity for stationary
phase.
It is then detected optically, identifying
the haemoglobin variants by their
retention times and quantified by
computing the area under
corresponding peak in elution profile.
Flow rate: 1.5mL/min
Pressure shouldn’t fluctuate >5%
WHY USE HPLC?
 Simultaneous analysis
 High resolution
 High sensitivity
 Good repeatability
 Easy to fractionate and detect
 Quantification is possible
 Less labour intensive
 Small sample is adequate
Though it is easy to detect and quantify haemoglobin variants , HPLC is a
screening tool and the definite confirmation is possible with DNA
analysis.
APPLICATION FIELDS
 Haemoglobin profiling in suspected haemoglobinopathies:
-Diagnosis of β Thalassemia Trait
-Diagnosis of rare Haemoglobins
-Diagnosis of Hereditary Persistance of Fetal Haemoglobin
-Antenatal screening for Thalassemia and Sickle Cell Disease
-Pre-operative screening of HbS cases
 HbA1C detection
 Pharmaceutical application
 Detect food adulterants
 To differentiate organic chemicals
 To differentiate proteins on basis of their structure
INTERPRETATION
PREREQUISITES:
 AGE (>1yrs)
 HAEMOGLOBINOPATHIES ARE INHERITED DISORDERS.
Ethnic background
Family history
 TRANSFUSION HISTORY (deferred if transfused within 3 months)
 DRUG HISTORY (hydroxyurea, azacytidine, cytarabine)
 Complete blood counts
 PREGNANCY- may elevate HbF
SAMPLE PREPARATION
 After addition of diluents , calibration check and control check,
The whole blood EDTA sample is prediluted with 5µL sample in 1.5ml wash
solution in aliquots.
 These aliquots arranged in a rack of 10 with 2 controls(low and high) are
then inserted to be run.
#Dilution should be according to haematocrit of the sample.
High Hct- 1:400 dilution
Low Hct- 1:100 dilution
CHROMATOGRAM
The receiver receives a voltage signal and plots it versus time. The area counts of the peak
for each component are calculated as a percentage of total area counts.
RT- retention time
CHROMATOGRAM
HbA2
PEAK
P3 VALUE-
Sample
quality
AREA
Within 1-
4 million
BASELINE
• At 0.02OD
• Curved,convex
• Properly
constructed
• <8%- acceptable
• 8-14% -
contamination
• >14% -HbJ variant
• should be present
• Symmetrical , sharp
• bell shaped
• TAC Less-increase sample ratio
• TAC high-decrease the sample ratio
EXCEPTION:
 Hb Lepore:
Baseline- inverted v shaped
RT- 3.5mins
coelutes with HbA2 and usually <20%
Elevation of HbF in range 3-7%
 HbD IRAN-
Baseline- inverted v shaped
split peak
Coelutes with HbA2 ranging from 40-
48%
Split peak- unknown peak before HbA2
and coelution with HbA2
RETENTION TIME?
 RETENTION TIME is the time in minutes from the
sample injection to the maximum point of the elution
peak of normal Haemoglobin and variant
Haemoglobins.
 It depends upon the type of Haemoglobin molecules.
BIO-RAD D10 values
PEAK RETENTION
TIME(MINS)
WINDOW(MINS) ACCEPTANCE
CRITERIA(%)
A1a 0.21 0.16-0.26 <2.5
A1b 0.29 0.23-0.35 <2.5
F 0.485 0.41-0.56
LA1c/CHb1 0.715 0.56-0.87 <4.0
LA1c/CHb2 0.735 0.60-0.87 <3.5
A1c 0.83 0.66-1.00 3.7-18.4
P3 1.43 1.23-1.63 <8.0
Ao 1.70 1.55-1.85
A2 3.01 2.59-3.43
S 4.16 4.02-4.30 >10
C 4.80 4.70-4.90
ORDER OF ELUTION
(with respect to retention time)
HbA2 HbD HbS HbQ HbC
D window/Unknown S window Unknown C window
@ 3.01mins @3.8mins @4.16mins @ 4.4mins @4.8mins
Alpha Thalassemia
HbH and Hb Barts are seen as preintegration sharp peaks @RT 0.60-0.70mins
ALPHA GENE VARIANTS
 Caused by Point Mutations leading to replacement of single
amino acid.
 HbJ Meerut - Haematological parameters are normal-mildly
decreased.
- sharp peak in P3 window with RT 1.6-1.85 mins.
- HbJ >14% is significant.
 HbQ India - Unknown window at RT 4.70-4.90min with a sharp
peak.
- Anaemia is absent but can be present along
with iron/folic acid/Vit B12 deficiency.
HbQ India
 Hb Godavari at RT 4.90-5.30 mins
 HbI Philadelphia at RT 1.28-1.30mins
 Hb Fontainbleau at RT 1.28-1.30mins at descending arm of
HbA
 Being single gene mutation, these conditions are clinically
silent and hence difficult to diagnose.
 Presentation: Anaemia
Familial cyanosis(alters oxygen affinity)
Familial Polycythemia
Microcytosis on PS
HbF(α2γ2)
 Results below range to be reported as <0.8%*.
 If HbF >16.5% - May elute in LA1c/CHb or A1c window and no HbF is reported.
 If HbF is absent – check for A1c/LA1c/CHb peaks.
If <3.5% - HbF absent
If HbF 5-15% with normal blood counts – may suggest HbF Trait
HPFH Δβ Thalassemia
HbF 15-45% Towards Lower value(~20%)
Normal indices Microcytosis
Positive modified Betke’s test Variable
Increased HbF can be seen in:
• Inherited red cell aplasia
• Diamond Blackfan Syndrome
• Fanconi’s Anaemia
• Erythropoietic stress(Haemolysis , bleeding)
HPLC.pptx
HbA2(α2δ2)
LOWER HIGH
Iron Deficiency Anaemia Megaloblastic Anaemia
Anaemia of Chronic Disease Sickle Cell Anaemia(4-4.5%) with associated α
Thalassemia
HbH Disease HIV +ve person on ART
Sideroblastic Anaemia Hyperthyroidism
Δβ Thalassemia Thalassemia Trait
HPLC.pptx
Beta Thalassemia Major(BIORAD variant)
• HbF levels are higher in
absence of β chain than
reduced synthesis.
• It ranges from 30-95%.
Beta Thalassemia Intermedia
• HbF is variable depending
upon whether the patient is
dependent on transfusion or
not.
• Marked increase of HbF(10-
35%) with concomitant
variable reduction in HbA
seen.
• HbA2 may be reduced/
normal/ elevated.
Beta Thalassemia Trait
• HbA2 = 3.9-8% is diagnostic.
• HbA2 3.3-3.7% -assess Iron status
As IDA decreases HbA2 levels.
Also B12 / Folic acid deficiency
increases HbA2 levels.
• HbF is normal/mildly increased
to 1-4%
• HbA2 = 7-9% usually found in
gujratis and sindhis.
BETA GENE VARIANTS
 HbE – Elutes with HbA2
 HbD – Unknown peak at 3.8 +/- 0.1 mins
 HbS – S window after HbA2
 HbC – C window
 22-50% - heterozygous condition
 70-90% - homozygous condition
 Compound conditions
HbE
(substitution of glutamic acid by lysine at β26 position)
HbE Trait
HbE coelutes with HbA2 (RT 3.69-3.79mins)
HbA2 <= 9% AND HbE >15%
Cases are clinically normal.
HbF usually normal.
HbE Disease
Major peak at A2 (85-95%).
RT similar as HbA2 BUT HbA2 <9% which helps to
differentiate A2 from HbE.
Cases have mild anaemia and splenomegaly.
HbF mildly increased/normal.
HbD
(substitution of glutamic acid by glutamine at β121 position)
Prevalent in Punjab and
Gujarat.
Cases are normal.
Detected when family
studies are carried out.
HbA2 is usually <2%
HbD TRAIT
HbD Disease
Presentation-
mild anaemia
with/without
splenomegaly.
D window 87.9%
at RT 4.20mins.
HbS
(substitution of glutamic acid by valine at β6 position)
HbS shows D window at
RT 4.30-4.50 mins.
HbS homozygous-
HbS = 70-90% total Hb
HbF = 10-30%
HbAo almost nil.
HbC
(substitution of glutamic acid by lysine at β6 position)
 HbC Trait cases are normal.
 HbC Disease cases have mild anaemia.
Cases on HPLC shows-
C Window ~75-90% at RT 4.90 -
5.30mins
HbC Disease
HbS - β Thalassemia
Clinical manifestation are variable
and severity depends on β
Thalassemia gene.
Red cell indices are decreased with
increased RBC count.
HPLC PATTERN-
HbS >50%
HbA 5-10%
HbF and HbA2 elevated.
HbE – β Thalassemia
Mutation in β chain and unstable nature
of HbE ~ SEVERITY
Variable presentation with decreased red
cell survival time.
HPLC PATTERN-
HbF -15-50% and HbE -50-80% in
untransfused cases.
HbA varies according to severity and may
be upto 25%.
HbD β-Thalassemia
Aymptomatic
Mild anaemia
Similar to β Thalassemia Trait
HPLC PATTERN-
HbD-70-90% as unknown peak
HbF- 3-20%
HbAo reduced.
HbA2 elevated
HbS-HbE
Asymptomatic
Mild anaemia
Paediatric patients have a milder
presentation than adults.
HPLC PATTERN-
HbS- 30-50%
HbE- 30-50%
HbA <10%
Mild elevation of HbF
HbS-HbD
Clinical presentation is of Sickle Cell
Anaemia.
Hb varies in the range of 6-10 g/dl.
HPLC PATTERN-
Unknown peak at RT 3.8mins <50%
HbS at S window <50%
HbF 10-20%
HbA2 -1.5-2.6%
Hereditary Persistence of Fetal
Haemoglobin(HPFH)
• Increased HbF in adults without
haematological abnormalities.
• Homozygous condition - total absence
of HbA with HbF >90%
• Heterozygous condition –
• HbF –10-30% with normal indices.
BILIRUBIN Preintegration peak
RT - < 0.63mins
COELUTION: DRAWBACK
 HbE and Hb Lepore may overlap HbA2.
 HbD IRAN may overlap HbA2.
 HbA2 falsely elevated in HbS upto 4-4.5%
 Increased HbF may elute in HbA1c peak.
 Increased HbA1c may elevate HbF.
 Increased Bilirubin in plasma gives preintegration peaks in
same areas as HbF and HbH.
REPORTED CASES
Parameters Observed value Reference Value (Adults)
Haemoglobin 11.8gm/dl 12-16 g/dl
PCV 33.9% M:40-50 ; F:36-46%
RBC count 5.56 M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8 M/cumm
MCV 60.9 fL 76-96 fL
MCH 21.2pg 27.5-31.5pg
MCHC 34.8g/dl 30-35 g/dl
RDW-CV 17.3 % 11.6-12.2 %
RDW-SD 36.2 fL 40.5-52.5 fL
RETIC COUNT: 4.5-5% Adults:0.5-2.5% ; Neonates:4-6%
PS : RBC series shows mild anisopoikilocytosis with Microcytic Hypochromic RBC’s.
Few elliptocytes seen.
Haemoglobin Chromatography
HbAo 82.6 % 95-98 %
HbA2 2.0 % 2.2-3.8 %
HbF 0.8% 00- 01 %
HbS 00% 00%
Impression: Hb HPLC report is suggestive of Normal Hb chromatography.
Disclamer: HPLC is not a screening test for α- Thalassemia.
Parameters Observed value Reference Value (Adults)
Haemoglobin 13.3gm/dl 12-16 g/dl
PCV 38.6% M:40-50% ; F:36-46%
RBC count 6.55M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8M/cumm
MCV 59.0 fL 76-96 fL
MCH 20.3pg 27.5-31.5pg
MCHC 34.4g/dl 30-35 g/dl
RDW-CV 17.7 % 11.6-12.2 %
RDW-SD 38.0 fL 40.5-52.5 fL
RETIC COUNT: 3-4% Adults:0.5-2.5% ; Neonates:4-6%
PS : RBC series shows mild to moderate anisopoikilocytosis with microcytic
hypochromic RBC’s. Few elliptocytes, schistocytes and target cells seen.
Haemoglobin Chromatography
HbAo 79.7% 95-98 %
HbA2 5.6% 2.2-3.8 %
HbF 0.9% 00- 01 %
HbS 00% 00%
Impression: Blood picture and increased HbA2 is suggestive of
β THALASSEMIA TRAIT.
Advice: Hb HPLC of siblings and spouse.
-DNA molecular study for confirmation.
Disclamer: HPLC is not a screening test for α- Thalassemia.
Parameters Observed value Reference Value (Adults)
Haemoglobin 15.8gm/dl 12-16 g/dl
PCV 42.5% M:40-50% ; F:36-46%
RBC count 5.20M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8M/cumm
MCV 81.7 fL 76-96 fL
MCH 30.4pg 27.5-31.5pg
MCHC 37.2g/dl 30-35 g/dl
RDW-CV 12.6 % 11.6-12.2 %
RDW-SD 42.0 fL 40.5-52.5 fL
RETIC COUNT: 01% Adults:0.5-2.5% ; Neonates:4-6%
SICKLING TEST: POSITIVE
PS : RBC series shows normocytic normochromic RBC’s. Occasional elliptocytes
and target cells seen.
Haemoglobin Chromatography
HbAo 48.3 % 95-98 %
HbA2 2.5% 2.2-3.8 %
HbF 0.8% 00- 01 %
HbS 38.9%(@ RT 4.15mins) 00%
Impression: Hb HPLC shows increased HbS, normal HbF and normal HbA2.
Blood picture and increased HbS is suggestive of SICKLE CELL TRAIT.
Advice: Hb HPLC of parents, siblings and in future spouse.
-DNA molecular study for confirmation.
Disclamer: HPLC is not a screening test for α- Thalassemia.
Parameters Observed value Reference Value (Adults)
Haemoglobin 6.5gm/dl 12-16 g/dl
PCV 21.6% M:40-50% ; F:36-46%
RBC count 62.29M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8 M/cumm
MCV 94.4fL 76-96 fL
MCH 28.4pg 27.5-31.5pg
MCHC 30.1g/dl 30-35 g/dl
RDW-CV 17.4% 11.6-12.2 %
RDW-SD 62.1 fL 40.5-52.5 fL
RETIC COUNT: 02% Adults:0.5-2.5% ; Neonates:4-6%
PS : RBC series : Decreased in total number with moderate degree of
anisopoikilocytosis showing normocytic normochromic and normocytic
hypochromic RBCs. Polychromatic cells, target cells, schistocytes, elliptocytes and
sickle shaped RBCs seen along with few microspherocytes.
Haemoglobin Chromatography
Test value Reference value
HbF 14.8% 00- 01 %
HbAo 2.9% 95-98 %
HbA2 1.2% 2.2-3.8 %
HbS 71.2% 00%
Impression: Blood picture, HPLC and positive sickling test are suggestive of
Sickle Cell disease.
Advice: Hb HPLC of siblings and spouse.
-DNA molecular study for confirmation.
Disclamer: HPLC is not a screening test for Sickle cell anaemia.
HPLC.pptx
TO SUMMARIZE:
RBC series on PS and Reticulocyte count to be
documented.
SPECIAL TESTS CHECKLIST- if not done , they are to be performed
simultaneously.
(sickling test, Modified Betke’s Test, Reticulocyte stain)
ASK FOR AGE,FAMILY HISTORY,TRANSFUSION
HISTORY,DRUG HISTORY,ETHNICITY
EDTA SAMPLE FOR HPLC+2 PS SLIDES
If all parameters are within normal range, proceed to read
the graphs.
Check for control readings- baseline , P3 value , HbA2
peak , Total area
Take 5µL Whole blood sample + 1.5ml wash solution in
aliquots and keep it in rack to be run.
Sample to be refrigerated until run in the HPLC system.
THANK YOU

More Related Content

PPTX
Preservation of microbes
PPTX
Chromatography
PPTX
Total iron binding capacity
PPTX
Calibration and Quality controls of automated hematology analyzer
PPTX
Osmotic fragility &amp; rbc membrane defects 050916
PPTX
Hemolytic anemia sandip
PPT
Hplc interpretation
PPTX
Establishment Of reference Interval
Preservation of microbes
Chromatography
Total iron binding capacity
Calibration and Quality controls of automated hematology analyzer
Osmotic fragility &amp; rbc membrane defects 050916
Hemolytic anemia sandip
Hplc interpretation
Establishment Of reference Interval

What's hot (20)

PPTX
Automation in Hematology part 2
PPTX
Hemoglobinopathies - Lab diagnosis
PPTX
Automation in hematology part 1
PPTX
NAAT IN BLOOD BANKING
PPT
Automated Urine Analysis
PPTX
Platelet Function Tests
PPTX
Hb electrophoresis (principle materials and procedure)
PDF
Leukocyte Alkaline Phosphatase Stain
PPTX
Interpretation of cbc 3
PPTX
Lecture 7.thalassemia
PPTX
Artefacts in hemat part 2
PPTX
Analytical and post analytical errors in laboratory
PDF
Automated tissue stainer - Xmatrx infinity
PPTX
WESTGARD RULES 2.pptx
PPTX
Gel card technology ppt nc
PPTX
reticulocyte.pptx
PPTX
Quality assurance in haematology
PPTX
Special stains in Bone marrow examination
PPTX
Discrepancies
PPTX
Automation in Hematology part 2
Hemoglobinopathies - Lab diagnosis
Automation in hematology part 1
NAAT IN BLOOD BANKING
Automated Urine Analysis
Platelet Function Tests
Hb electrophoresis (principle materials and procedure)
Leukocyte Alkaline Phosphatase Stain
Interpretation of cbc 3
Lecture 7.thalassemia
Artefacts in hemat part 2
Analytical and post analytical errors in laboratory
Automated tissue stainer - Xmatrx infinity
WESTGARD RULES 2.pptx
Gel card technology ppt nc
reticulocyte.pptx
Quality assurance in haematology
Special stains in Bone marrow examination
Discrepancies
Ad

Similar to HPLC.pptx (20)

PDF
HPLC Subject seminar.pdf
PPTX
HPLC Pathology PG topic for exam High Imp
PPTX
thalassemia
PPTX
HPLCCHARTS__2__lyst1600 (1).pptx important topic
PPT
Thalassaemia (Genetic Disorder of Hemoglobin)
PPT
Interpreting Abnormal hemoglobin study
PPT
High Performance Liquid chromatography INTERPRETATION.ppt
PPTX
Haemoglobin ss
PPTX
LabORATORY daigonosis thalassemia Chirantan Man
PPTX
Laboratory Diagonosis thalassemia Chirantan
PDF
capillary electrophoresis by high performance liquid chromatography
PPT
Glycosylated Hb.ppt
PPTX
Approach to hemolytic anemia naglaa
PDF
DMLT (1st Year) : Blood Hemoglobin, Blood Glucose estimation and Urine routin...
PPTX
Glycated haemoglobin ppt by Basalingappa BG
PPTX
High Performance Liquid Chromatography(HPLC).pptx
PDF
Hemoglobin estimation
PPTX
Lab data interpretation in pediatrics
PPTX
Haemoglobin Electrophoresis for Hb disorders
HPLC Subject seminar.pdf
HPLC Pathology PG topic for exam High Imp
thalassemia
HPLCCHARTS__2__lyst1600 (1).pptx important topic
Thalassaemia (Genetic Disorder of Hemoglobin)
Interpreting Abnormal hemoglobin study
High Performance Liquid chromatography INTERPRETATION.ppt
Haemoglobin ss
LabORATORY daigonosis thalassemia Chirantan Man
Laboratory Diagonosis thalassemia Chirantan
capillary electrophoresis by high performance liquid chromatography
Glycosylated Hb.ppt
Approach to hemolytic anemia naglaa
DMLT (1st Year) : Blood Hemoglobin, Blood Glucose estimation and Urine routin...
Glycated haemoglobin ppt by Basalingappa BG
High Performance Liquid Chromatography(HPLC).pptx
Hemoglobin estimation
Lab data interpretation in pediatrics
Haemoglobin Electrophoresis for Hb disorders
Ad

More from aditisikarwar2 (20)

PPTX
NYSDOH-AI-Prevention-and-Management-of-Hepatitis-B-Virus-Infection-in-Adults-...
PPTX
classificationoflungtumors-190205112941 (1).pptx
PPTX
1_Dr Jasmita Das Peripheral blood smear examination with Romanowsky stains.pptx
PPTX
HEMATOXYLINE AND EOSIN STAINING in histopptx
PPTX
crossmatching-200827073022.pptx
PPTX
5_6264545646183712730.pptx
PDF
Granulomatous Disease Residents.pdf
PPTX
9_Dr Poonam Panjwani Basic principles of IHC.pptx
PPTX
1422 Dr Tanaya Grossing Whipples .pptx
PPTX
5_6264545646183712730.pptx
PPTX
APR.pptx
PPTX
1422 Dr Tanaya Grossing Whipples .pptx
PPTX
ROLE OF DIGITAL IMAGING IN PATHOLOGY.pptx
PPTX
prion diseases.pptx
PPTX
pedagogy.pptx
PPTX
Quality control.pptx
PPTX
bone marrow ppt.pptx
PPTX
GROSSING OF BREAST.pptx
PPTX
STAINS IN HISTOPATHOLOGY.pptx
PPTX
APHERESIS-1.pptx
NYSDOH-AI-Prevention-and-Management-of-Hepatitis-B-Virus-Infection-in-Adults-...
classificationoflungtumors-190205112941 (1).pptx
1_Dr Jasmita Das Peripheral blood smear examination with Romanowsky stains.pptx
HEMATOXYLINE AND EOSIN STAINING in histopptx
crossmatching-200827073022.pptx
5_6264545646183712730.pptx
Granulomatous Disease Residents.pdf
9_Dr Poonam Panjwani Basic principles of IHC.pptx
1422 Dr Tanaya Grossing Whipples .pptx
5_6264545646183712730.pptx
APR.pptx
1422 Dr Tanaya Grossing Whipples .pptx
ROLE OF DIGITAL IMAGING IN PATHOLOGY.pptx
prion diseases.pptx
pedagogy.pptx
Quality control.pptx
bone marrow ppt.pptx
GROSSING OF BREAST.pptx
STAINS IN HISTOPATHOLOGY.pptx
APHERESIS-1.pptx

Recently uploaded (20)

PPTX
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
PDF
شيت_عطا_0000000000000000000000000000.pdf
PPT
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PPTX
Clinical approach and Radiotherapy principles.pptx
PDF
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PPTX
anal canal anatomy with illustrations...
PDF
Human Health And Disease hggyutgghg .pdf
PPT
HIV lecture final - student.pptfghjjkkejjhhge
PPT
Obstructive sleep apnea in orthodontics treatment
PPTX
Respiratory drugs, drugs acting on the respi system
PPTX
Note on Abortion.pptx for the student note
PPT
STD NOTES INTRODUCTION TO COMMUNITY HEALT STRATEGY.ppt
PPT
ASRH Presentation for students and teachers 2770633.ppt
PPTX
neonatal infection(7392992y282939y5.pptx
PPTX
Transforming Regulatory Affairs with ChatGPT-5.pptx
PPTX
ACID BASE management, base deficit correction
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PPTX
Important Obstetric Emergency that must be recognised
PPT
OPIOID ANALGESICS AND THEIR IMPLICATIONS
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
شيت_عطا_0000000000000000000000000000.pdf
Copy-Histopathology Practical by CMDA ESUTH CHAPTER(0) - Copy.ppt
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
Clinical approach and Radiotherapy principles.pptx
focused on the development and application of glycoHILIC, pepHILIC, and comm...
anal canal anatomy with illustrations...
Human Health And Disease hggyutgghg .pdf
HIV lecture final - student.pptfghjjkkejjhhge
Obstructive sleep apnea in orthodontics treatment
Respiratory drugs, drugs acting on the respi system
Note on Abortion.pptx for the student note
STD NOTES INTRODUCTION TO COMMUNITY HEALT STRATEGY.ppt
ASRH Presentation for students and teachers 2770633.ppt
neonatal infection(7392992y282939y5.pptx
Transforming Regulatory Affairs with ChatGPT-5.pptx
ACID BASE management, base deficit correction
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
Important Obstetric Emergency that must be recognised
OPIOID ANALGESICS AND THEIR IMPLICATIONS

HPLC.pptx

  • 1. HPLC Principle, Uses, Interpretation, Results MODERATOR: PRESENTED BY: Dr. Maneesh Sulya Dr. Parul Murab
  • 2. HPLC? HIGH PERFORMANCE: Originally referred as high pressure liquid chromatography since high pressure is applied using a pump system. Due to its high efficiency and performance, it is now referred as high performance. LIQUID CHROMATOGRAPHY: A physical method of separation, identification and quantification of components in which components to be separated are distributed between a liquid mobile phase and a solid stationary phase in a definite direction.
  • 3. INTRODUCTION: CHROMATOGRAPHY  Chromatography is a physical method of separation between: STATIONARY PHASE MOBILE PHASE The substance on which adsorption Solvent which carries the analyte. of analyte takes place. Can be solid, gel, liquid or Can be liquid or gas. combination.  TECHNIQUE IS DIVIDED ON BASIS OF: Chromatographic bed: column or planar Physical state of mobile phase: gas or liquid Separation mechanism: adsorption, ion exchange , ion pair , affinity, gel permeation Elution techniques: Isocratic , gradient Scale of operation: analytical(no recovery) , preparative
  • 4. SYSTEM TYPE?  LIQUID CHROMATOGRAPHY: Liquid mobile phase  COLUMN CHROMATOGRAPHY: Adsorption of substance on stationary phase. -Separation of adsorbed substance using mobile phase. -recovery of individual components by continuous flow of mobile phase.  HIGH PRESSURE CHROMATOGRAPHY-15-75kg/cm²  ION EXCHANGE( cation) OR ADSORPTION MECHANISM or both.  GRADIENT ELUTION TECHNIQUE  REVERSED PHASE Chromatography-non polar stationary phase and polar mobile phase.
  • 6. PRINCIPLE Mixture of molecules (normal and variant haemoglobin) with a net positive charge is separated into its components by their adsorption onto a negatively charged stationary phase(resin) in chromatographic column/cartridge.
  • 7. Cations in the mobile phase(buffer A and B) competes with adsorbed proteins(haemoglobin molecules) for anionic binding sites. Buffer A: weak affinity for anionic binding sites. Buffer B: strong affinity for anionic binding sites.
  • 8. The adsorbed positively charged haemoglobin molecules are eluted from column into liquid phase at a rate related to their affinity for stationary phase. It is then detected optically, identifying the haemoglobin variants by their retention times and quantified by computing the area under corresponding peak in elution profile. Flow rate: 1.5mL/min Pressure shouldn’t fluctuate >5%
  • 9. WHY USE HPLC?  Simultaneous analysis  High resolution  High sensitivity  Good repeatability  Easy to fractionate and detect  Quantification is possible  Less labour intensive  Small sample is adequate Though it is easy to detect and quantify haemoglobin variants , HPLC is a screening tool and the definite confirmation is possible with DNA analysis.
  • 10. APPLICATION FIELDS  Haemoglobin profiling in suspected haemoglobinopathies: -Diagnosis of β Thalassemia Trait -Diagnosis of rare Haemoglobins -Diagnosis of Hereditary Persistance of Fetal Haemoglobin -Antenatal screening for Thalassemia and Sickle Cell Disease -Pre-operative screening of HbS cases  HbA1C detection  Pharmaceutical application  Detect food adulterants  To differentiate organic chemicals  To differentiate proteins on basis of their structure
  • 12. PREREQUISITES:  AGE (>1yrs)  HAEMOGLOBINOPATHIES ARE INHERITED DISORDERS. Ethnic background Family history  TRANSFUSION HISTORY (deferred if transfused within 3 months)  DRUG HISTORY (hydroxyurea, azacytidine, cytarabine)  Complete blood counts  PREGNANCY- may elevate HbF
  • 13. SAMPLE PREPARATION  After addition of diluents , calibration check and control check, The whole blood EDTA sample is prediluted with 5µL sample in 1.5ml wash solution in aliquots.  These aliquots arranged in a rack of 10 with 2 controls(low and high) are then inserted to be run. #Dilution should be according to haematocrit of the sample. High Hct- 1:400 dilution Low Hct- 1:100 dilution
  • 14. CHROMATOGRAM The receiver receives a voltage signal and plots it versus time. The area counts of the peak for each component are calculated as a percentage of total area counts. RT- retention time
  • 15. CHROMATOGRAM HbA2 PEAK P3 VALUE- Sample quality AREA Within 1- 4 million BASELINE • At 0.02OD • Curved,convex • Properly constructed • <8%- acceptable • 8-14% - contamination • >14% -HbJ variant • should be present • Symmetrical , sharp • bell shaped • TAC Less-increase sample ratio • TAC high-decrease the sample ratio
  • 16. EXCEPTION:  Hb Lepore: Baseline- inverted v shaped RT- 3.5mins coelutes with HbA2 and usually <20% Elevation of HbF in range 3-7%
  • 17.  HbD IRAN- Baseline- inverted v shaped split peak Coelutes with HbA2 ranging from 40- 48% Split peak- unknown peak before HbA2 and coelution with HbA2
  • 18. RETENTION TIME?  RETENTION TIME is the time in minutes from the sample injection to the maximum point of the elution peak of normal Haemoglobin and variant Haemoglobins.  It depends upon the type of Haemoglobin molecules.
  • 19. BIO-RAD D10 values PEAK RETENTION TIME(MINS) WINDOW(MINS) ACCEPTANCE CRITERIA(%) A1a 0.21 0.16-0.26 <2.5 A1b 0.29 0.23-0.35 <2.5 F 0.485 0.41-0.56 LA1c/CHb1 0.715 0.56-0.87 <4.0 LA1c/CHb2 0.735 0.60-0.87 <3.5 A1c 0.83 0.66-1.00 3.7-18.4 P3 1.43 1.23-1.63 <8.0 Ao 1.70 1.55-1.85 A2 3.01 2.59-3.43 S 4.16 4.02-4.30 >10 C 4.80 4.70-4.90
  • 20. ORDER OF ELUTION (with respect to retention time) HbA2 HbD HbS HbQ HbC D window/Unknown S window Unknown C window @ 3.01mins @3.8mins @4.16mins @ 4.4mins @4.8mins
  • 21. Alpha Thalassemia HbH and Hb Barts are seen as preintegration sharp peaks @RT 0.60-0.70mins
  • 22. ALPHA GENE VARIANTS  Caused by Point Mutations leading to replacement of single amino acid.  HbJ Meerut - Haematological parameters are normal-mildly decreased. - sharp peak in P3 window with RT 1.6-1.85 mins. - HbJ >14% is significant.  HbQ India - Unknown window at RT 4.70-4.90min with a sharp peak. - Anaemia is absent but can be present along with iron/folic acid/Vit B12 deficiency.
  • 24.  Hb Godavari at RT 4.90-5.30 mins  HbI Philadelphia at RT 1.28-1.30mins  Hb Fontainbleau at RT 1.28-1.30mins at descending arm of HbA  Being single gene mutation, these conditions are clinically silent and hence difficult to diagnose.  Presentation: Anaemia Familial cyanosis(alters oxygen affinity) Familial Polycythemia Microcytosis on PS
  • 25. HbF(α2γ2)  Results below range to be reported as <0.8%*.  If HbF >16.5% - May elute in LA1c/CHb or A1c window and no HbF is reported.  If HbF is absent – check for A1c/LA1c/CHb peaks. If <3.5% - HbF absent If HbF 5-15% with normal blood counts – may suggest HbF Trait
  • 26. HPFH Δβ Thalassemia HbF 15-45% Towards Lower value(~20%) Normal indices Microcytosis Positive modified Betke’s test Variable Increased HbF can be seen in: • Inherited red cell aplasia • Diamond Blackfan Syndrome • Fanconi’s Anaemia • Erythropoietic stress(Haemolysis , bleeding)
  • 28. HbA2(α2δ2) LOWER HIGH Iron Deficiency Anaemia Megaloblastic Anaemia Anaemia of Chronic Disease Sickle Cell Anaemia(4-4.5%) with associated α Thalassemia HbH Disease HIV +ve person on ART Sideroblastic Anaemia Hyperthyroidism Δβ Thalassemia Thalassemia Trait
  • 30. Beta Thalassemia Major(BIORAD variant) • HbF levels are higher in absence of β chain than reduced synthesis. • It ranges from 30-95%.
  • 31. Beta Thalassemia Intermedia • HbF is variable depending upon whether the patient is dependent on transfusion or not. • Marked increase of HbF(10- 35%) with concomitant variable reduction in HbA seen. • HbA2 may be reduced/ normal/ elevated.
  • 32. Beta Thalassemia Trait • HbA2 = 3.9-8% is diagnostic. • HbA2 3.3-3.7% -assess Iron status As IDA decreases HbA2 levels. Also B12 / Folic acid deficiency increases HbA2 levels. • HbF is normal/mildly increased to 1-4% • HbA2 = 7-9% usually found in gujratis and sindhis.
  • 33. BETA GENE VARIANTS  HbE – Elutes with HbA2  HbD – Unknown peak at 3.8 +/- 0.1 mins  HbS – S window after HbA2  HbC – C window  22-50% - heterozygous condition  70-90% - homozygous condition  Compound conditions
  • 34. HbE (substitution of glutamic acid by lysine at β26 position) HbE Trait HbE coelutes with HbA2 (RT 3.69-3.79mins) HbA2 <= 9% AND HbE >15% Cases are clinically normal. HbF usually normal. HbE Disease Major peak at A2 (85-95%). RT similar as HbA2 BUT HbA2 <9% which helps to differentiate A2 from HbE. Cases have mild anaemia and splenomegaly. HbF mildly increased/normal.
  • 35. HbD (substitution of glutamic acid by glutamine at β121 position) Prevalent in Punjab and Gujarat. Cases are normal. Detected when family studies are carried out. HbA2 is usually <2% HbD TRAIT
  • 37. HbS (substitution of glutamic acid by valine at β6 position) HbS shows D window at RT 4.30-4.50 mins. HbS homozygous- HbS = 70-90% total Hb HbF = 10-30% HbAo almost nil.
  • 38. HbC (substitution of glutamic acid by lysine at β6 position)  HbC Trait cases are normal.  HbC Disease cases have mild anaemia. Cases on HPLC shows- C Window ~75-90% at RT 4.90 - 5.30mins HbC Disease
  • 39. HbS - β Thalassemia Clinical manifestation are variable and severity depends on β Thalassemia gene. Red cell indices are decreased with increased RBC count. HPLC PATTERN- HbS >50% HbA 5-10% HbF and HbA2 elevated.
  • 40. HbE – β Thalassemia Mutation in β chain and unstable nature of HbE ~ SEVERITY Variable presentation with decreased red cell survival time. HPLC PATTERN- HbF -15-50% and HbE -50-80% in untransfused cases. HbA varies according to severity and may be upto 25%.
  • 41. HbD β-Thalassemia Aymptomatic Mild anaemia Similar to β Thalassemia Trait HPLC PATTERN- HbD-70-90% as unknown peak HbF- 3-20% HbAo reduced. HbA2 elevated
  • 42. HbS-HbE Asymptomatic Mild anaemia Paediatric patients have a milder presentation than adults. HPLC PATTERN- HbS- 30-50% HbE- 30-50% HbA <10% Mild elevation of HbF
  • 43. HbS-HbD Clinical presentation is of Sickle Cell Anaemia. Hb varies in the range of 6-10 g/dl. HPLC PATTERN- Unknown peak at RT 3.8mins <50% HbS at S window <50% HbF 10-20% HbA2 -1.5-2.6%
  • 44. Hereditary Persistence of Fetal Haemoglobin(HPFH) • Increased HbF in adults without haematological abnormalities. • Homozygous condition - total absence of HbA with HbF >90% • Heterozygous condition – • HbF –10-30% with normal indices.
  • 46. COELUTION: DRAWBACK  HbE and Hb Lepore may overlap HbA2.  HbD IRAN may overlap HbA2.  HbA2 falsely elevated in HbS upto 4-4.5%  Increased HbF may elute in HbA1c peak.  Increased HbA1c may elevate HbF.  Increased Bilirubin in plasma gives preintegration peaks in same areas as HbF and HbH.
  • 48. Parameters Observed value Reference Value (Adults) Haemoglobin 11.8gm/dl 12-16 g/dl PCV 33.9% M:40-50 ; F:36-46% RBC count 5.56 M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8 M/cumm MCV 60.9 fL 76-96 fL MCH 21.2pg 27.5-31.5pg MCHC 34.8g/dl 30-35 g/dl RDW-CV 17.3 % 11.6-12.2 % RDW-SD 36.2 fL 40.5-52.5 fL RETIC COUNT: 4.5-5% Adults:0.5-2.5% ; Neonates:4-6% PS : RBC series shows mild anisopoikilocytosis with Microcytic Hypochromic RBC’s. Few elliptocytes seen. Haemoglobin Chromatography HbAo 82.6 % 95-98 % HbA2 2.0 % 2.2-3.8 % HbF 0.8% 00- 01 % HbS 00% 00% Impression: Hb HPLC report is suggestive of Normal Hb chromatography. Disclamer: HPLC is not a screening test for α- Thalassemia.
  • 49. Parameters Observed value Reference Value (Adults) Haemoglobin 13.3gm/dl 12-16 g/dl PCV 38.6% M:40-50% ; F:36-46% RBC count 6.55M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8M/cumm MCV 59.0 fL 76-96 fL MCH 20.3pg 27.5-31.5pg MCHC 34.4g/dl 30-35 g/dl RDW-CV 17.7 % 11.6-12.2 % RDW-SD 38.0 fL 40.5-52.5 fL RETIC COUNT: 3-4% Adults:0.5-2.5% ; Neonates:4-6% PS : RBC series shows mild to moderate anisopoikilocytosis with microcytic hypochromic RBC’s. Few elliptocytes, schistocytes and target cells seen. Haemoglobin Chromatography HbAo 79.7% 95-98 % HbA2 5.6% 2.2-3.8 % HbF 0.9% 00- 01 % HbS 00% 00% Impression: Blood picture and increased HbA2 is suggestive of β THALASSEMIA TRAIT. Advice: Hb HPLC of siblings and spouse. -DNA molecular study for confirmation. Disclamer: HPLC is not a screening test for α- Thalassemia.
  • 50. Parameters Observed value Reference Value (Adults) Haemoglobin 15.8gm/dl 12-16 g/dl PCV 42.5% M:40-50% ; F:36-46% RBC count 5.20M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8M/cumm MCV 81.7 fL 76-96 fL MCH 30.4pg 27.5-31.5pg MCHC 37.2g/dl 30-35 g/dl RDW-CV 12.6 % 11.6-12.2 % RDW-SD 42.0 fL 40.5-52.5 fL RETIC COUNT: 01% Adults:0.5-2.5% ; Neonates:4-6% SICKLING TEST: POSITIVE PS : RBC series shows normocytic normochromic RBC’s. Occasional elliptocytes and target cells seen. Haemoglobin Chromatography HbAo 48.3 % 95-98 % HbA2 2.5% 2.2-3.8 % HbF 0.8% 00- 01 % HbS 38.9%(@ RT 4.15mins) 00% Impression: Hb HPLC shows increased HbS, normal HbF and normal HbA2. Blood picture and increased HbS is suggestive of SICKLE CELL TRAIT. Advice: Hb HPLC of parents, siblings and in future spouse. -DNA molecular study for confirmation. Disclamer: HPLC is not a screening test for α- Thalassemia.
  • 51. Parameters Observed value Reference Value (Adults) Haemoglobin 6.5gm/dl 12-16 g/dl PCV 21.6% M:40-50% ; F:36-46% RBC count 62.29M/cumm M:4.5-5.5 M/cumm ;F:3.8-4.8 M/cumm MCV 94.4fL 76-96 fL MCH 28.4pg 27.5-31.5pg MCHC 30.1g/dl 30-35 g/dl RDW-CV 17.4% 11.6-12.2 % RDW-SD 62.1 fL 40.5-52.5 fL RETIC COUNT: 02% Adults:0.5-2.5% ; Neonates:4-6% PS : RBC series : Decreased in total number with moderate degree of anisopoikilocytosis showing normocytic normochromic and normocytic hypochromic RBCs. Polychromatic cells, target cells, schistocytes, elliptocytes and sickle shaped RBCs seen along with few microspherocytes. Haemoglobin Chromatography Test value Reference value HbF 14.8% 00- 01 % HbAo 2.9% 95-98 % HbA2 1.2% 2.2-3.8 % HbS 71.2% 00% Impression: Blood picture, HPLC and positive sickling test are suggestive of Sickle Cell disease. Advice: Hb HPLC of siblings and spouse. -DNA molecular study for confirmation. Disclamer: HPLC is not a screening test for Sickle cell anaemia.
  • 53. TO SUMMARIZE: RBC series on PS and Reticulocyte count to be documented. SPECIAL TESTS CHECKLIST- if not done , they are to be performed simultaneously. (sickling test, Modified Betke’s Test, Reticulocyte stain) ASK FOR AGE,FAMILY HISTORY,TRANSFUSION HISTORY,DRUG HISTORY,ETHNICITY EDTA SAMPLE FOR HPLC+2 PS SLIDES
  • 54. If all parameters are within normal range, proceed to read the graphs. Check for control readings- baseline , P3 value , HbA2 peak , Total area Take 5µL Whole blood sample + 1.5ml wash solution in aliquots and keep it in rack to be run. Sample to be refrigerated until run in the HPLC system.

Editor's Notes

  • #4: Isocratic-mobile phase comp remains same throughout. Peak width inc with RT-late eluting peaks Gradient- mobile phase composition is changed during separation. Dec RT of late eluting peaks hence peak is narrower and is fast
  • #5: Gradient- mobile phase composition is changed during separation. Dec RT of late eluting peaks hence peak is narrower and is fast
  • #7: used for detection of Abnormal Hb molecules in Thalassemias and various hempoglobinopathies.
  • #8: Sodium phosphate buffer
  • #13: Reactivation
  • #22: HbH INCLUSIONS-SUPRAVITAL STAIN
  • #23: α120 alanine replaces glutamic acid α64 aspartate replaces histidine
  • #26: NGSP-NATIONAL GLYCOHAEMOGLOBIN STANDARDISATION PROGRAMME
  • #27: Hereditary marrow failure /ar/ chromosaomal breakage and ineffective dna repair Cytopenias/ncnc/retic low/bm hypocellular/stress erythropoiesis-inter normoblasts Cong chronic aregenerative anaemia/ad/defect in ribosome synthesis Anaemia in first 2 yrs /low retic/wbc platelet normal/selective def of erythroblasts
  • #35: After HbS, next most prevalent variant. A2 , E , HbD IRAN elute at same time. A2<9% / E 15-30% / HbD iran >40% (broad based curve which doesn’t touch baseline.
  • #55: WASH SOLUTION- DEIONIZED WATER